Biologic Safety Myths in Elderly Psoriasis Patients Under Scrutiny
Age alone is not a contraindication to biologic therapy in psoriasis, yet elderly patients remain undertreated as safety myths persist, a new Dermatology Times analysis argues.
Topic
Biologics
Topic
Biologics
Debunking Biologic Safety Myths in Elderly Psoriasis Patients
Age alone should not disqualify older psoriasis patients from biologics, argues a Dermatology Times analysis dismantling persiste…
Optimizing Hidradenitis Suppurativa Care: Biologics, Combos, Surgery
Expert guidance from HCPlive focuses on optimizing HS biologics, combination therapy and surgical timing in hidradenitis suppurat…
GLP-1 Combination Therapy Signals New Benefits in Psoriasis
NewsNation reports GLP-1 combination therapy may unlock new benefits for psoriasis patients, extending the metabolic-skin overlap…
Review reframes AD and psoriasis as dynamic immune processes
A Frontiers review reframes atopic dermatitis and psoriasis as dynamic immune processes, arguing static histopathology misses imm…
Guselkumab Shows Efficacy for Inverse Psoriasis: Case Report
A Frontiers case report and literature review concludes guselkumab is effective for inverse psoriasis, adding IL-23 evidence to a…
Liver Function Test Elevations Rare With Biologics in Psoriasis and HS
Liver function test elevations occur rarely in psoriasis and HS patients on biologics, Dermatology Times reports — supporting str…
Fall Clinical 2026 First Half Recap Spotlights Psoriasis and Atopic Dermatitis
HCPLive's Fall Clinical 2026 first-half recap leads with psoriasis and atopic dermatitis, rounding up the Las Vegas congress's op…
Litifilimab Sustains Skin Clearance Through 52 Weeks in Cutaneous Lupus
Litifilimab, an investigational type I interferon-targeting biologic, maintained durable skin clearance through 52 weeks in patie…
Dermatomyositis Therapies Expand, MedPage Today Reports
MedPage Today reports the treatment options for dermatomyositis are evolving, with biologics and biomarker-informed algorithms re…